ASP-7517

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameASP-7517
Drug Alias NameASP-7517
ClassificationCell and gene therapy > Cell therapy > Source of cells > HEK293 cell line-derivedCell and gene therapy > Cell therapy > Somatic cell > Artificial adjuvant vector cell
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Global Development IncAstellas Pharma China Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A